Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms

Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer

(2020) Morten Orebo Holmström et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms

(2020) Morten Orebo Holmström et al.   Cancers

LBA48 Clinical efficacy and immunity of combination therapy with nivolumab and IDO/PD-L1 peptide vaccine in patients with metastatic melanoma: A phase I/II trial

(2020) I-M. Svane et al.   ANNALS OF ONCOLOGY

Healthy Donors Harbor Memory T Cell Responses to RAS Neo-Antigens

(2020) Morten Orebo Holmström et al.   Cancers

High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals

(2019) Morten O. Holmström et al.   Blood Cancer Journal

Programmed Cell Death Receptor (PD-1) Ligand (PD-L1) expression in Philadelphia chromosome-negative myeloproliferative neoplasms

(2019) Jen-Chin Wang et al.   LEUKEMIA RESEARCH

Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population

(2019) Sabrina Cordua et al.   BLOOD

Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T Cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms

(2019) Cansu Cimen Bozkus et al.   Cancer Discovery

Immunosuppression by Mutated Calreticulin Released from Malignant Cells

(2019) Peng Liu et al.   MOLECULAR CELL

Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer

(2019) Harm Westdorp et al.   Journal for ImmunoTherapy of Cancer

Tumor-associated calreticulin variants functionally compromise the peptide loading complex and impair its recruitment of MHC-I

(2018) Najla Arshad et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The T-win® technology: immune-modulating vaccines

(2018) Mads Hald Andersen   Seminars in Immunopathology

Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response

(2018) Morten Orebo Holmström et al.   OncoImmunology

Spontaneous T-cell responses against Arginase-1 in chronic myeloproliferative neoplasms relative to disease stage and type of driver mutation

(2018) Mia Aaboe Jørgensen et al.   OncoImmunology

Perspectives on interferon-alpha in the treatment of Polycythemia vera and related Myeloproliferative neoplasms: minimal residual disease and cure?

(2018) Hans Carl Hasselbalch et al.   Seminars in Immunopathology

The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy

(2017) M O Holmström et al.   LEUKEMIA

Sorted peripheral blood cells identify CALR mutations in B- and T-lymphocytes

(2017) Lasse Kjaer et al.   LEUKEMIA & LYMPHOMA

Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer

(2017) Vinod P. Balachandran et al.   NATURE

Myeloproliferative Neoplasms

(2017) Jerry L. Spivak   NEW ENGLAND JOURNAL OF MEDICINE

The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy

(2017) Shamaila Munir Ahmad et al.   OncoImmunology

Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis

(2017) Marco Romano et al.   OncoImmunology

Frequent adaptive immune responses against arginase-1

(2017) Evelina Martinenaite et al.   OncoImmunology

Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms

(2016) M. Araki et al.   BLOOD

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

(2016) Alexander M. Lesokhin et al.   JOURNAL OF CLINICAL ONCOLOGY

Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion

(2016) Lijuan Han et al.   Journal of Hematology & Oncology

PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies

(2016) M H Qazilbash et al.   LEUKEMIA

Thrombopoietin receptor is required for the oncogenic function of CALR mutants

(2016) H Nivarthi et al.   LEUKEMIA

The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms

(2016) M O Holmström et al.   LEUKEMIA

The impact of interferon-alpha2 on HLA genes in patients with polycythemia vera and related neoplasms

(2016) Vibe Skov et al.   LEUKEMIA & LYMPHOMA

Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm

(2016) Jen Chin Wang et al.   LEUKEMIA RESEARCH

Circulating Calreticulin Is Increased in Myelofibrosis: Correlation with Interleukin-6 Plasma Levels, Bone Marrow Fibrosis, and Splenomegaly

(2016) Daria Sollazzo et al.   MEDIATORS OF INFLAMMATION

Anti-regulatory T cells

(2016) Mads Hald Andersen   Seminars in Immunopathology

Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation

(2016) S. Elf et al.   Cancer Discovery

Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants

(2015) I. Chachoua et al.   BLOOD

JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms

(2015) Kathrin Schönberg et al.   CANCER RESEARCH

Therapeutic cancer vaccines

(2015) Cornelis J.M. Melief et al.   JOURNAL OF CLINICAL INVESTIGATION

Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone

(2015) J-J Kiladjian et al.   LEUKEMIA

Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera

(2015) Cecilie Utke Rank et al.   LEUKEMIA & LYMPHOMA

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis

(2014) E. Rumi et al.   BLOOD

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis

(2014) A. Tefferi et al.   BLOOD

Is the "3+3" Dose-Escalation Phase I Clinical Trial Design Suitable for Therapeutic Cancer Vaccine Development? A Recommendation for Alternative Design

(2014) O. E. Rahma et al.   CLINICAL CANCER RESEARCH

Expansion of circulating CD56brightnatural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α

(2014) Caroline H. Riley et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Nasopharyngeal Hodgkin Lymphoma

(2014) Matthew E. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

Mechanisms of Jak/STAT Signaling in Immunity and Disease

(2014) Alejandro V. Villarino et al.   JOURNAL OF IMMUNOLOGY

The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors

(2014) Osama E Rahma et al.   Journal of Translational Medicine

Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation

(2014) V Panagiota et al.   LEUKEMIA

An Immune Dysregulation in MPN

(2014) Giovanni Barosi   Current Hematologic Malignancy Reports

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

(2013) A. Tefferi et al.   BLOOD

The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo

(2013) A. Heine et al.   BLOOD

Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project

(2013) G. Barosi et al.   BLOOD

Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut)

(2013) J. Greiner et al.   BLOOD

HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer Patients

(2013) S. Munir et al.   CANCER RESEARCH

Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase

(2013) T. Z. Iversen et al.   CLINICAL CANCER RESEARCH

Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2

(2013) J. Nangalia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms

(2013) Thorsten Klampfl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting

(2012) Evgeny Klyuchnikov et al.   BRITISH JOURNAL OF HAEMATOLOGY

Skin-Test Infiltrating Lymphocytes Early Predict Clinical Outcome of Dendritic Cell-Based Vaccination in Metastatic Melanoma

(2012) E. H. J. G. Aarntzen et al.   CANCER RESEARCH

A Comprehensive Survey of Ras Mutations in Cancer

(2012) I. A. Prior et al.   CANCER RESEARCH

New insights of T cells in the pathogenesis of psoriasis

(2012) Yihua Cai et al.   Cellular & Molecular Immunology

Re-emergence of interferon-α in the treatment of chronic myeloid leukemia

(2012) M Talpaz et al.   LEUKEMIA

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

Natural CD4+ T-Cell Responses against Indoleamine 2,3-Dioxygenase

(2012) Shamaila Munir et al.   PLoS One

Increase in circulating CD4+CD25+Foxp3+ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN- 

(2011) C. H. Riley et al.   BLOOD

Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

(2011) Tiziano Barbui et al.   JOURNAL OF CLINICAL ONCOLOGY

Response definition criteria for ELISPOT assays revisited

(2010) Z. Moodie et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Autoimmunity and the risk of myeloproliferative neoplasms

(2010) S. Y. Kristinsson et al.   HAEMATOLOGICA

Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras

(2010) Synne Wedén et al.   INTERNATIONAL JOURNAL OF CANCER

Development of Different Analysis Platforms with LC−MS for Pharmacokinetic Studies of Protein Drugs

(2009) Qiaozhen Lu et al.   ANALYTICAL CHEMISTRY

Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia

(2009) Gemma G. Kenter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

(2008) J.-J. Kiladjian et al.   BLOOD

Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers

(2008) Antoun Toubaji et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY